Maryland-based Altimmune Inc., a clinical stage biopharmaceutical company, has submitted an Investigational New Drug, or IND, application to the United States Food and Drug Administration to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.
Researchers in Japan have revealed a previously unknown mechanism for pain control involving a newly identified group of cells in the spinal cord, offering a potential target for enhancing the therapeutic effect of drugs for chronic pain.
The covid-19 virus, like all viruses relies on their host for reproduction
A new therapy for influenza virus infections that may also prove effective against many other pathogenic virus infections, including HIV and COVID-19, has been developed by Purdue University scientists.
A hallmark of Parkinson's disease is the degeneration of a group of neurons in the brain that release the neurotransmitter dopamine (dopaminergic neurons)
Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy—a scientific first and major advance for the field of regenerative medicine. The discovery, published in the Proceedings of the National Academy of Sciences (PNAS), could improve current stem cell therapies designed to treat such neurological disorders as spinal cord injury, stroke, amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders; and expand their use to new conditions, such as heart disease or arthritis.
Craig Jordan, PhD, has spent more than 20 years developing better treatments for acute myeloid leukemia (AML), a rapidly progressing cancer of the blood and bone marrow that can spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system.
New York University, Columbia University, and Takeda Pharmaceutical Company Limited (“Takeda”) have formed a collaborative research alliance to begin and advance gastroenterology research programs, with the goal of developing new therapies for patients with gastrointestinal and liver disorders.
Giving nurse practitioners the authority to prescribe buprenorphine has brought that gold standard treatment for opioid addiction to people who might not have had access to it before, according to a new study led by Tracy Klein, PhD, associate professor at the Washington State University College of Nursing in Vancouver.
Antibiotics may be a good treatment choice for some appendicitis patients, according to early results from the Comparing Outcomes of antibiotic Drugs and Appendectomy (CODA) trial reported in the New England Journal of Medicine.
Specifically, Dr. Susan Reed talked about research into drugs that act at the kisspeptin/neurokinin B/ dynorphin (KNDy) neuron complex in the hypothalamus which controls reproduction and hormonal control. During menopause, estrogen levels decrease, which causes these neurons to be hyperstimulated, thereby causing hot flashes.
A widely used tuberculosis vaccine is associated with reduced likelihood of contracting COVID-19 (coronavirus), according to a new study by Cedars-Sinai. The findings raise the possibility that a vaccine already approved by the U.S. Food and Drug Administration may help prevent coronavirus infections or reduce severity of the disease.
Using a combination of AI and supercomputing resources, Argonne researchers are examining the dynamics of the SARS-CoV-2 spike protein to determine how it fuses with the human host cell, advancing the search for drug treatments.
Older adults are at a disproportionate risk of severe COVID-19 disease, so it is essential that any vaccine adopted for use against SARS-CoV-2 is effective in this group
By combing the ocean for antimicrobials, scientists at the University of Wisconsin–Madison have discovered a new antifungal compound that efficiently targets multi-drug-resistant strains of deadly fungi without toxic side effects in mice.
ore than 1.1 million Medicare patients could die over the next decade because they cannot afford to pay for their prescription medications, according to a new study released today by the West Health Policy Center, a nonprofit and nonpartisan policy research group and Xcenda, the research arm of the drug distributor AmerisourceBergen.
A team from Roswell Park Comprehensive Cancer Center has detailed striking findings on the effectiveness of a previously untried combination of old and new drugs as treatment for recurrent ovarian cancer.
The Huntsman Cancer Institute, College of Pharmacy and PIVOT Center have partnered to establish the University of Utah Therapeutic Accelerator Hub. The new Accelerator will provide resources and expertise to researchers to support the process of translating research discoveries into innovative clinical applications.
Researchers at Washington University School of Medicine in St. Louis have identified a molecule that protects mice from brain infections caused by Venezuelan equine encephalitis virus (VEEV), a mosquito-borne virus notorious for causing fast-spreading, deadly outbreaks in Mexico, Central America and northern South America.
在回顾性病例研究中，妙佑医疗国际(Mayo Clinic)的研究人员发现，对2岁以下儿童使用抗生素与一些难以治愈的病症存在关联，其中包括过敏症和肥胖症。这项研究结果发表在Mayo Clinic Proceedings上。
A machine learning model developed by a team of Lawrence Livermore National Laboratory (LLNL) scientists to aid in COVID-19 drug discovery efforts is a finalist for the Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research.
New research has shown that the antidepressant sertraline helps to inhibit the growth of cancer cells. The substance acts on a metabolic addiction that allows different types of cancer to grow.
Researchers at Karolinska Institutet in Sweden report promising results from an in vitro combination therapy against COVID-19.
People taking dummy pills and statins experienced similar side effects in a new study.
Pancreatic cancer is difficult to detect and treat, so researchers are continually advancing working on understanding of the disease through research. Rutgers Cancer Institute of New Jersey expert shares an overview of research and treatment advances for pancreatic cancer.
The December edition of SLAS Discovery, “Drug Discovery Targeting COVID-19” is a special collection assembled by Associate Editor Timothy Spicer (Scripps, FL, USA), focusing on drug discovery efforts toward the current global pandemic of COVID-19caused by the novel coronavirus, SARS-CoV-2.
Mild cognitive impairment affects millions of seniors. There is no curative drug. Seven possibly helpful supplements gleaned from medical journal articles are described
For the first time, a medication has impacted heart muscle thickness and function for patients with the most common inherited heart condition, hypertrophic cardiomyopathy, rather than simply addressing their symptoms.
Researchers at the Department of Energy’s Oak Ridge National Laboratory investigated the binding properties of several hepatitis C drugs to determine how well they inhibit the SARS-CoV-2 main protease, a crucial protein enzyme that enables the novel coronavirus to reproduce. Inhibiting, or blocking, the protease from functioning is vital to stopping the virus from spreading in patients with COVID-19.
Apple Tree Partners (ATP), a leading life sciences venture firm, today announced the launch of Nereid Therapeutics, a company dedicated to discovering new disease treatments by applying pioneering research and technologies in biomolecular condensates.
In a retrospective case study, Mayo Clinic researchers have found that antibiotics administered to children younger than 2 are associated with several ongoing illnesses or conditions, ranging from allergies to obesity. The findings appear in Mayo Clinic Proceedings.
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol—the so-called “bad” cholesterol—by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found.
Mount Sinai clinical trial results could help lead to FDA approval
Rapid Reviews: COVID-19 (RR:C19) is an open-access overlay journal published by the MIT Press that accelerates peer review of COVID-19-related research preprints.
Bristol scientists have demonstrated a new virtual reality [VR] technique which should help in developing drugs against the SARS-CoV-2 virus - and enable researchers to share models and collaborate in new ways.
Researchers at the University of Maryland School of Medicine (UMSOM) have discovered new drug compounds to potentially treat the novel coronavirus that causes COVID-19. This finding could lead to the development of new broad-spectrum antiviral drugs that target viruses such as influenza, Ebola and coronaviruses.
The information came from the International Polycap Study 3 (TIPS-3) study which followed the participants an average of 4.6 years. The study of 5,714 people from nine countries, particularly India and the Philippines, looked at the polypill alone compared to a placebo; aspirin alone versus a placebo, and the polypill plus aspirin versus a double placebo. The men in the study were 50 or older and the women were 55 or older.
Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that ursodeoxycholic acid (UDCA) treatment has significant, positive results for patients with primary sclerosing cholangitis (PSC), including reduced incidence of biliary tract cancer, reduced mortality and less need for liver transplant.
A new Vanderbilt-designed prediction model may make it easier to determine which infants will go on to develop neonatal abstinence syndrome (NAS), a drug withdrawal syndrome in newborns that occurs after exposure to opioids during pregnancy.
An Indiana University Melvin and Bren Simon Comprehensive Cancer Center researcher has been awarded a five-year, $2.9 million grant from the National Cancer Institute to develop a drug that could make radiation therapy far more effective.
Researchers at Washington University School of Medicine in St. Louis have completed a clinical trial suggesting that the antidepressant drug fluvoxamine may help prevent deterioration in COVID-19 patients, making hospitalization less likely.
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) .
Analysis update by the nonprofit Cancer Research Institute reveals dramatic growth in PD-1/PD-L1 monoclonal antibody combination cancer treatment strategies in global clinical trial pipeline
The ongoing global pandemic has created an urgent need for rapid tests that can diagnose the presence of the SARS-CoV-2 virus, the pathogen that causes COVID-19, and distinguish it from other respiratory viruses.
Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right